Generating AI analysis...
Revenue
$11.2B
-5.60% YoY
EPS (Basic)
$1.21
++120.54% YoY
Evidence Layer
| Metric | Current | Previous | YoY Change |
|---|---|---|---|
Revenue | $11.2B | $11.87B | -5.60% |
Cost of Revenue | $3.03B | $2.93B | +3.44% |
Net Income | $2.46B | $-11.91B | +120.62% |
EPS (Basic) | $1.21 | $-5.89 | +120.54% |
EPS (Diluted) | $1.20 | $-5.89 | +120.37% |
R&D Expense | $2.26B | $2.69B | -16.25% |
SG&A Expense | $1.58B | $2.37B | -33.08% |
| Metric | Current | Previous | YoY Change |
|---|---|---|---|
Total Assets | $92.43B | $99.03B | -6.67% |
Current Assets | $30.78B | $28.67B | +7.37% |
Total Liabilities | $74.98B | $82.48B | -9.10% |
Current Liabilities | $24.07B | $25.82B | -6.78% |
Stockholders' Equity | $17.39B | $16.49B | +5.45% |
Cash & Equivalents | $10.88B | $9.33B | +16.56% |
Long-Term Debt | $49.51B | $52.36B | -5.45% |
| Metric | Current | Previous | YoY Change |
|---|---|---|---|
Operating Cash Flow | $1.95B | $2.83B | -31.05% |
Investing Cash Flow | $-499M | $-19.62B | +97.46% |
Financing Cash Flow | $-993M | $14.64B | -106.78% |
Dividends Paid | $1.26B | $1.21B | +3.80% |
D&A | $1.01B | $2.53B | -60.03% |
| Metric | Current | Previous | YoY Change |
|---|---|---|---|
Net Margin | 21.9% | — | — |
ROE | 14.1% | — | — |
ROA | 2.7% | — | — |
Current Ratio | $1.279 | — | — |
Debt to Equity | $4.312 | — | — |
Other companies in Pharmaceuticals